GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neovasc Inc (NAS:NVCN) » Definitions » Cyclically Adjusted PS Ratio

Neovasc (Neovasc) Cyclically Adjusted PS Ratio : (As of May. 06, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Neovasc Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Neovasc Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Neovasc's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neovasc Cyclically Adjusted PS Ratio Chart

Neovasc Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Neovasc Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Neovasc's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Neovasc's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neovasc's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neovasc's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Neovasc's Cyclically Adjusted PS Ratio falls into.



Neovasc Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Neovasc's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2022 is calculated as:

For example, Neovasc's adjusted Revenue per Share data for the three months ended in Dec. 2022 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=0.528/120.9639*120.9639
=0.528

Current CPI (Dec. 2022) = 120.9639.

Neovasc Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201303 987.500 97.103 1,230.156
201306 1,327.000 97.182 1,651.737
201309 1,761.500 97.419 2,187.232
201312 1,427.500 96.945 1,781.175
201403 1,735.000 98.604 2,128.432
201406 2,064.000 99.473 2,509.915
201409 1,912.500 99.394 2,327.532
201412 1,581.500 98.367 1,944.801
201503 1,152.500 99.789 1,397.053
201506 975.667 100.500 1,174.329
201509 824.667 100.421 993.363
201512 741.333 99.947 897.218
201603 669.000 101.054 800.812
201606 570.333 102.002 676.359
201609 1,011.333 101.765 1,202.135
201612 920.333 101.449 1,097.375
201703 493.667 102.634 581.835
201706 435.000 103.029 510.725
201709 458.333 103.345 536.474
201712 307.000 103.345 359.340
201803 56.667 105.004 65.280
201806 7.500 105.557 8.595
201809 6.413 105.636 7.344
201812 4.670 105.399 5.360
201903 3.640 106.979 4.116
201906 1.612 107.690 1.811
201909 1.667 107.611 1.874
201912 1.844 107.769 2.070
202003 1.220 107.927 1.367
202006 0.581 108.401 0.648
202009 0.784 108.164 0.877
202012 0.547 108.559 0.610
202103 0.231 110.298 0.253
202106 0.234 111.720 0.253
202109 0.260 112.905 0.279
202112 0.280 113.774 0.298
202203 0.225 117.646 0.231
202206 0.300 120.806 0.300
202209 0.336 120.648 0.337
202212 0.528 120.964 0.528

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Neovasc  (NAS:NVCN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Neovasc Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Neovasc's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Neovasc (Neovasc) Business Description

Traded in Other Exchanges
N/A
Address
13562 Maycrest Way, Suite 5138, Richmond, BC, CAN, V6V 2J7
Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.

Neovasc (Neovasc) Headlines